MG-132

Catalog No.S2619

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Cited by 58 Publications

11 Customer Reviews

  • Western blot of IκBζ expression in BMDMs treated with DI and stimulated with LPS for 1 h. MG132 or bafilomycin A (BafA) were added 30 min before LPS stimulation.

    Nature, 2018, 556(7702):501-504. MG-132 purchased from Selleck.

    MDA-MB-231 cells were treated with 10 uM MG132 and incubated under normoxia or hypoxia for 4 h. Endogenous interaction between LATS2 and SIAH2 was analysed by immunoprecipitation.

    Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck.

  • HeLa cells were transfected with control mimic, RMND5A siRNA or miR-138 mimic. After transfection for 36 h, cells were treated with proteasome inhibitor MG132 (20 uM) or Dimethyl sulfoxide (DMSO) for 8 h. Endogenous Exportin-5 protein and RMND5A protein expression was measured by western blotting.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

    HeLa cells were transfected with negative control mimic, miR-138 mimic or RMND5A siRNA. After transfection for 36 h, cells were treated with MG132 (20 uM) or DMSO for 8 h. RMND5A and Exportin-5 protein expression were analyzed by immunocytochemistry. Nuclei were counterstained with DAPI.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

  •  

    TFEB induced autophagy dependent ATZ clearance in vitro. MEF transiently co-transfected with either ATZ plus GFP expressing plasmids or ATZ plus TFEB expressing plasmids were incubated with proteasome inhibitor MG132 or with DMSO for 6 h. Upon MG132 treatment, steady state levels of 52 kDa ATZ band increased in both cells transfected with ATZ plus GFP and with ATZ plus TFEB expressing plasmids. Quantification of band intensities showed a 48% reduction of ATZ in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP, in the absence of the proteasome inhibitor. In MG132 treated cells, a 61% decrease of ATZ was detected in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP.

    EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck.

    JAK1 expression was analyzed in A375 cells expressing scrambled shRNA or shRNF125 (#2) and treated with MG132 (5 uM, 10 hr), and in Lu1205 cells expressing WT RNF125 and treated with MG132.

    Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck.

  • LRB1 and LRB2 regulate phyB protein levels. PhyB protein levels in crude extracts from the wild type (WT) and the indicated mutant backgrounds were assayed by immunoblot analysis with anti-phyB monoclonal antibodies. Anti-PBA1 and anti-histone H3 antibodies were used to confirm equal protein loading. Rc-induced loss of phyB in the wild type is inhibited by 100 uM MG132.

    Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck.

    Representative images for γ-H2AX-stained cells treated with 100 uM FA for 3 h without or with MG132. Fluorescence was measured in at least 50 nuclei in each of three experiments.

    Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck.

  • Nek2A impedes SuFu ubiquitination. HEK293T cells transfected with Nek2A-Myc and Flag-SuFu for 48 h were treated with MG-132 to enrich ubiquitinated proteins, and subsequently subjected to co-immunoprecipitation assay. Precipitated proteins were probed using anti-Ub antibody.

    Int J Oncol, 2017, 50(2):373-380. MG-132 purchased from Selleck.

    GSK-3β phosphorylation at Ser9 is enhanced in NOK-overexpressed stable cell lines. The proteasome inhibitor, MG132, was added in medium of HeLa-HA and HeLa-NOK-HA cells for 12 h and then the p-GSK-3b(Ser9) was assayed by western blotting.

    FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck.

  • Truncated mouse Period2 (Per2) protein was expressed in NIH3T3 cells, treated by cycloheximide with or without MG132 for 1-4 hours.Per2 was reported to be degraded by the proteasome proteolysis. By adding MG132 (25 μM), a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment (shown by western blot).

    2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Targets
20S proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells M3fOPGZ2dmO2aX;uJGF{e2G7 NXruZZk{OjVizszN MnnkSG1UVw>? M4TZVGlvcGmkaYTzJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjFizszN M33ROFI1Pjl5NEm2
HL-60 MWHDfZRwfG:6aXOgRZN{[Xl? NIjxW2U1OCEQvF2= NYnIUJJMPDhiaB?= MluzSG1UVw>? NXj4e4FPUUN3MEyxNEDPxE1? NWfKdos{OjR4OUe0PVY>
SMMC-7721 NEPmSFJEgXSxdH;4bYMhSXO|YYm= MUW0NEDPxE1? M1HSWlQ5KGh? M1LrNWROW09? M3L0XmlEPTB;Nz6xJO69VQ>? M4HsVVI1Pjl5NEm2
A-549 MUjDfZRwfG:6aXOgRZN{[Xl? MoHEOFAh|ryP NVPFWpY2PDhiaB?= NIj4TpZFVVOR M1zON2lEPTB:MUCg{txO MkfaNlQ3QTd2OU[=
MCF-7 M3LYOWN6fG:2b4jpZ{BCe3OjeR?= NEm1XJE1OCEQvF2= NXTRS3YxPDhiaB?= NHj0T5lFVVOR MX7JR|UxRTdwMzFOwG0> NXvjOmQyOjR4OUe0PVY>
SW-480 MlrQR5l1d3SxeHnjJGF{e2G7 M{G3cVQxKM7:TR?= NYPlT4lXPDhiaB?= NUX5To9nTE2VTx?= NWruemhoUUN3ME20JO69VQ>? M{L3RlI1Pjl5NEm2
NCI-H929 M1jSV2N6fG:2b4jpZ{BCe3OjeR?= NFvvdYsyKM7:TR?= MWC3NkBp MoDtSG1UVw>? Mo\rTWM2OD1yLkG3JO69VQ>? MknnNlQ3OjVyOEi=
293T MV3DfZRwfG:6aXOgRZN{[Xl? NWLjR21rOTBizszN MYC3NkBp MU\EUXNQ M3j6UmlEPTB:MjFOwG0> NULVSmdwOjR4MkWwPFg>
293T MU\GeY5kfGmxbjDBd5NigQ>? NGDqb4cyOCEQvF2= M37yNlI1KGh? M4XTW2ROW09? M3nhb21w\GW{YYTlcJkhcW6mdXPld{Bp\WG2LYPoc4NsKCB? MkTaNlQ3OjVyOEi=
HeLa NYq2dG5NU2mwYYPlJGF{e2G7 NV\LT3JEOTBizszN M1;FUFEhcA>? Mkf0SG1UVw>? NYrIXXYzUW6mdXPld{BRSVKSIHPs[YF3[WenIHL5JIlvcGmkaYTpcocheHKxc3Xhd49u\SCjY4Tpeol1gQ>? MkHmNlQ{OjF6M{O=
MDA-MB-231 NFXndldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjFSXcyKM7:TR?= MVG3NkBp M1HuSWROW09? MUnJR|UxRTBwMUig{txO NIC5R3czPDF3M{KwOi=>
MCF-7 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[xJO69VQ>? M3;GTVczKGh? MoW2SG1UVw>? NXHpd2NUUUN3ME2wMlE{KM7:TR?= MlfSNlQyPTN{ME[=
MCF10A NIHxOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq5NUDPxE1? Mnq5O|IhcA>? MWXEUXNQ M3PNZ2lEPTB;MD6yPUDPxE1? MYqyOFE2OzJyNh?=
HEK-293 NX;XWWtGU2mwYYPlJGF{e2G7 M{fZSlIh[W6mIEKwJO69VQ>? MWmyJIg> NIDte|lFVVOR NH;re|RKdmirYnn0d{BEcFRvTDDhZ5Rqfmm2eTD3bZRpKEmFNUCgc4YhQSCwTTC= M3G2ZlI{PTRyN{mw
Calu6 NVL3XZN[TnWwY4Tpc44hSXO|YYm= Mn74NVAh|ryP NIjoXoYyQCCq M{jFUGROW09? MXPTbYdvcW[rY3HueIx6KGGlY4XteYxifGW|IH\yZZRigGmwIIDy[YN2enOxch?= NXn1Z5ZjOjN3ME[0PFY>
IFN-gamma-induced RAW264.7 NFHYeYVHfW6ldHnvckBCe3OjeR?= Mk\CSG1UVw>? M3jOXGlvcGmkaYTzJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjB5NzFOwG0> MmfxNlIzPzd{N{e=
IPC227F MX7DfZRwfG:6aXOgRZN{[Xl? Mny3NUDPxE1? NXzK[GNmPDhiaB?= MUPEUXNQ M3jJfWlEPTB;MD6wO|ch|ryP M1jOPFIyQTJ2NUK4
Hepa-1c1c7 M3m3ZWZ2dmO2aX;uJGF{e2G7 M4P5WlI2KM7:TR?= NYPq[FR7PiCq M3zBWWROW09? M1jtZmlv[3KnYYPld{BPemZ{IIDyc5RmcW5ibHX2[Yw> MnXrNlA{QTJ3NES=
COS-7 MXLDfZRwfG:6aXOgRZN{[Xl? MmXUNVAh|ryP NX64V4MzTE2VTx?= NYO4VmlHUUN3MEyxNEDPxE1? MXqxPFA5QDB7Nx?=
HuH-7 MWXDfZRwfG:6aXOgRZN{[Xl? NVTPdJY4OTBizszN NVrYUY5xTE2VTx?= NUDkbld7UUN3MEyxNEDPxE1? NWjhPFFMOThyOEiwPVc>
OCI-Ly3 MnnFSpVv[3Srb36gRZN{[Xl? NWD6dpU6OTBizszNxsA> M1PmdFQhcA>? MVrEUXNQ MmPBTY5lfWOnczDoeY1idiCLa3HwdIFD[WyyaHGgd5Ri[mmuaYrheIlwdiC5aYToJGVEPTBib3[gNUDPxE1? NYPXd5p1OThyMkSxNVM>
A2780 cDDP M3HDdGFxd3C2b4Ppd{BCe3OjeR?= M3i0flI1KGh? Mn\SSG1UVw>? NGi2NYdKdmS3Y3XzJIFxd3C2b4Ppd{BjgSCrbnjpZol1cW6pIGDUSW4h\GWpcnHkZZRqd25? NYfjW4RiOTd4OESwNVg>
LPS-stimulated RAW264.7 cells M3qyOWZ2dmO2aX;uJGF{e2G7 NYLNeYlpTE2VTx?= Mn2wTY5pcWKrdIOgUmYuc2GycHHCJGRPSSCkaX7kbY5o MkXaNVc1ODd{N{e=
PC12 NULPTWk2TnWwY4Tpc44hSXO|YYm= MVqxNFAh|ryPwrC= NHfFWW8zPCCq M2XMZmROW09? MXjJcohq[mm2czC2MW9JTEFvIHHu[EBJOk9{LXnu[JVk\WRiY4n0c5RwgGmlaYT5 M1e5UFE4OTV6NEW0
PC3 M{D6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTJNlAh|ryP NVLKd5Q{PDhiaB?= M3L2emROW09? NGr0[HFKSzVyPUCuOkDPxE1? MUixOlY5PjV|Nx?=
LP-1 M2j0fWFxd3C2b4Ppd{BCe3OjeR?= MYezNFAhdk1? M{H2UFI1KGh? MWfEUXNQ MkToTY5lfWOnczDhdI9xfG:|aYOgZpkhcW6lcnXhd4lv\yClbHXheoVlKFCDUmCgcIV3\WxiYX7kJJJm\HWlaX7nJG1kdC1zIIDyc5RmcW5ibHX2[Yw> MWKxOVk2QDV6OR?=
ES6 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMEGzNFYh|ryP NH7VVGxUSU6JRWK=
A101D MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDiTWM2OD1yLkCzNlc6KM7:TR?= M3vTVHNCVkeHUh?=
OCUB-M MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nzO2lEPTB;MD6wN|c{PyEQvF2= MVjTRW5ITVJ?
LB2518-MEL NGHlR2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMEO3OkDPxE1? NVPlfIZtW0GQR1XS
SH-4 NGjBUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\vTYFUUUN3ME2wMlA1OzFizszN MkTCV2FPT0WU
KNS-42 NUf3W3hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH4dI1yUUN3ME2wMlA1PDRzIN88US=> MVfTRW5ITVJ?
DSH1 M2DRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMEWyPFkh|ryP NFjvcW5USU6JRWK=
NTERA-S-cl-D1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfoOXVKSzVyPUCuNFU4PzJizszN NWHBUHBoW0GQR1XS
D-542MG NFf6NJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEW5OVch|ryP MlrzV2FPT0WU
KS-1 M2rkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTRSYJYUUN3ME2wMlA3PDV6IN88US=> NInoOWxUSU6JRWK=
BL-41 M{\Ebmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLwSIpJUUN3ME2wMlA3QTR5IN88US=> MorTV2FPT0WU
LXF-289 MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPzTWM2OD1yLkC3NFY3KM7:TR?= NHfxNYFUSU6JRWK=
D-247MG NYix[VNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEeyNFkh|ryP NH3sbYZUSU6JRWK=
MMAC-SF MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4exXmlEPTB;MD6wO|I3QCEQvF2= MUTTRW5ITVJ?
CP66-MEL NFvq[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXVdGJKSzVyPUCuNFc2KM7:TR?= MWHTRW5ITVJ?
LB771-HNC M3XqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMEiwN|Yh|ryP M2i0eXNCVkeHUh?=
no-10 MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHFTWM2OD1yLkC4PVA6KM7:TR?= NGnPO45USU6JRWK=
A388 MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPCfWZKSzVyPUCuNFkxPjVizszN MXvTRW5ITVJ?
OPM-2 NWfmU|lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW5TWM2OD1yLkGwOFc1KM7:TR?= M3LaXHNCVkeHUh?=
OVCAR-4 M3viV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMUC5N|gh|ryP NUfOVnhZW0GQR1XS
HOP-62 NF7sWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCyTWM2OD1yLkGwPVQ6KM7:TR?= MY\TRW5ITVJ?
ML-2 NUnFfG1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi2TWM2OD1yLkGxPFA3KM7:TR?= MXPTRW5ITVJ?
UACC-257 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n1XmlEPTB;MD6xNVkzPyEQvF2= M2LUTnNCVkeHUh?=
NEC8 NFHjem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXRXpVKSzVyPUCuNVE6QTVizszN MWHTRW5ITVJ?
ONS-76 M1LZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH1NGE{UUN3ME2wMlEzQTN3IN88US=> NFrFWJRUSU6JRWK=
KE-37 Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnmVGw4UUN3ME2wMlE{Ojd6IN88US=> M2CxVHNCVkeHUh?=
HT-144 NF3k[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLySpU{UUN3ME2wMlE{QDl3IN88US=> MV7TRW5ITVJ?
LB2241-RCC M3\zWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvRc2FIUUN3ME2wMlE1OjR5IN88US=> MoHyV2FPT0WU
TE-5 NUnxbm5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fSTWlEPTB;MD6xOFI4QCEQvF2= NWjHb3A4W0GQR1XS
KINGS-1 MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jmbWlEPTB;MD6xOFc6KM7:TR?= MnyyV2FPT0WU
NCI-H69 M13qdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TzUWlEPTB;MD6xOVE1OSEQvF2= NG\KW|lUSU6JRWK=
CAS-1 M2Sy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH6TWM2OD1yLkG1OFgzKM7:TR?= NVjV[4gyW0GQR1XS
D-263MG NIG3NYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMU[wNFYh|ryP NHP6UJFUSU6JRWK=
A253 MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMU[xNlgh|ryP NXLKU2VRW0GQR1XS
PF-382 NEjoZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GxOGlEPTB;MD6xOlcxPiEQvF2= NV;FVYpUW0GQR1XS
CESS M4rNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnOwTWM2OD1yLkG3NFYh|ryP M{PxT3NCVkeHUh?=
MZ2-MEL NYLoUVVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLZTWM2OD1yLkG3OVU6KM7:TR?= MVPTRW5ITVJ?
HEL M3q3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP1WGlKSzVyPUCuNVg2OTdizszN NEm3RpVUSU6JRWK=
D-392MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XZcmlEPTB;MD6xPVEyPSEQvF2= MVvTRW5ITVJ?
SK-LMS-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMUmzNFMh|ryP NEX5ToZUSU6JRWK=
GI-ME-N NFjs[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMUmzNFYh|ryP MkDPV2FPT0WU
LB831-BLC NGC3cWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT0TWM2OD1yLkG5N|Qh|ryP NHzpPZpUSU6JRWK=
DU-4475 NHTUU41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHaXpRtUUN3ME2wMlE6PjV6IN88US=> NGfuWXFUSU6JRWK=
IST-SL1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj6Tmd{UUN3ME2wMlIxODl2IN88US=> NXXEcZB[W0GQR1XS
GAK Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlOxTWM2OD1yLkKwOVM1KM7:TR?= M4LXRXNCVkeHUh?=
EW-1 NX7YTHFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTZTWM2OD1yLkKxNFQ4KM7:TR?= MYjTRW5ITVJ?
LAMA-84 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH5SIFKSzVyPUCuNlE5PTFizszN MoXmV2FPT0WU
SK-UT-1 NIW4PYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMkKwOFkh|ryP MVPTRW5ITVJ?
VA-ES-BJ MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;PWWxKSzVyPUCuNlIzPTdizszN NF\SOXVUSU6JRWK=
ACN M3zaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH75S3RKSzVyPUCuNlI3OzhizszN NHnCdItUSU6JRWK=
SK-PN-DW MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHDTWM2OD1yLkKzNVkh|ryP NYPzdGx6W0GQR1XS
HD-MY-Z MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMkOzNFMh|ryP NXLtVYVnW0GQR1XS
LB373-MEL-D NHWxWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;EPJJLUUN3ME2wMlI1OTl6IN88US=> NW\EbpNbW0GQR1XS
COLO-829 NFqze21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLkXY52UUN3ME2wMlI1OjV5IN88US=> Mm\YV2FPT0WU
ES8 M4fFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;lbFlVUUN3ME2wMlI1PzZ|IN88US=> NEPheZpUSU6JRWK=
RXF393 MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPUdpNKSzVyPUCuNlUxOTVizszN NVu5SnBGW0GQR1XS
TK10 NXjj[I1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[2TWM2OD1yLkK1OFM2KM7:TR?= MnP1V2FPT0WU
LOUCY M4fsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jqTmlEPTB;MD6yOVQ2PiEQvF2= NHLwR2VUSU6JRWK=
MZ7-mel NWLPfHZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXycIxCUUN3ME2wMlI3Ozd2IN88US=> M1;VU3NCVkeHUh?=
CP67-MEL MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMk[3N{DPxE1? MnPhV2FPT0WU
C2BBe1 NVHjTIh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlexTWM2OD1yLkK3PVA4KM7:TR?= MVTTRW5ITVJ?
K052 NF;xT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL2[HJKSzVyPUCuNlg6QSEQvF2= NFHlXnJUSU6JRWK=
MOLT-16 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\vcndKSzVyPUCuNlk2OjRizszN MYPTRW5ITVJ?
KNS-81-FD MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TjWmlEPTB;MD6zNFMzOyEQvF2= NHrBfVBUSU6JRWK=
CMK NYTOc2l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS5dnlqUUN3ME2wMlMyOTJizszN MUHTRW5ITVJ?
LAN-6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwM{GzJO69VQ>? NX;BfpR[W0GQR1XS
KLE M2DlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu3R2RKSzVyPUCuN|E{ODZizszN NVnlOYY2W0GQR1XS
NCCIT MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwM{G3PFMh|ryP NHrBXGhUSU6JRWK=
HH MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XQSGlEPTB;MD6zNlg6PyEQvF2= NXm2VHNkW0GQR1XS
TE-8 NE\QWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL1TWM2OD1yLkO0Nlc6KM7:TR?= NFn0c|NUSU6JRWK=
GDM-1 NGGwUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnjTWM2OD1yLkO1NVA1KM7:TR?= M{Kzc3NCVkeHUh?=
NCI-H747 NHvjS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnoOpk6UUN3ME2wMlM4OTB|IN88US=> Mn7NV2FPT0WU
NCI-H1092 M1rQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17XbmlEPTB;MD6zPFg1PCEQvF2= MWfTRW5ITVJ?
8-MG-BA NUjjSW9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XsOWlEPTB;MD6zPVg{PyEQvF2= MWfTRW5ITVJ?
NB17 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwNEK5O{DPxE1? NIfPUG1USU6JRWK=
LC4-1 MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfVTWM2OD1yLkSzOlA4KM7:TR?= MmK5V2FPT0WU
TE-1 Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrUfYFsUUN3ME2wMlQ2OTF7IN88US=> M{nHUHNCVkeHUh?=
KALS-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jtVmlEPTB;MD60OlU5PCEQvF2= M3nSPHNCVkeHUh?=
CCRF-CEM NXfV[GtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnThTWM2OD1yLkS3Olc1KM7:TR?= NU\DTWJ6W0GQR1XS
OS-RC-2 M3n5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHJTWM2OD1yLkS3PVczKM7:TR?= NUX4fG9lW0GQR1XS
A704 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:1b5hKSzVyPUCuOFg3QTJizszN M{PHTHNCVkeHUh?=
BB49-HNC NGHaSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrINIhKSzVyPUCuOFkxQTZizszN MlL5V2FPT0WU
EVSA-T NHTzRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TKXmlEPTB;MD60PVkyOSEQvF2= NX7iNnBsW0GQR1XS
Mo-T Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGW1fZFKSzVyPUCuOVE4PjJizszN M3jVRXNCVkeHUh?=
MONO-MAC-6 Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{faemlEPTB;MD61N|YyOSEQvF2= MnPSV2FPT0WU
BB65-RCC M1;C[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzkfFRxUUN3ME2wMlU3QDFzIN88US=> NV3QSnhJW0GQR1XS
NCI-H1882 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvmNHlKSzVyPUCuOVkxOzZizszN MVzTRW5ITVJ?
TE-9 M1rMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjmOGNMUUN3ME2wMlYyODN|IN88US=> NI\jSWlUSU6JRWK=
NCI-H2126 NUW5bodRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwNkK2Olkh|ryP Mn\ZV2FPT0WU
SF268 NFjp[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwNkW2OFEh|ryP NYHCd5dbW0GQR1XS
SW872 NIL2Z3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLHOJBKSzVyPUCuOlU4OjlizszN NILDWnpUSU6JRWK=
LS-513 NXmybVRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\2Xm1SUUN3ME2wMlY3PzVzIN88US=> NVjLWlhDW0GQR1XS
NCI-H1355 M4S5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTxdVc3UUN3ME2wMlY5PjF7IN88US=> NXX3eHNWW0GQR1XS
BL-70 NVnmSGJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjITWM2OD1yLk[5N|g5KM7:TR?= NGjFSFdUSU6JRWK=
NCI-SNU-5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXiTFZKSzVyPUCuOlk2PDVizszN M{XEVHNCVkeHUh?=
SNU-C2B Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml35TWM2OD1yLkewO|M6KM7:TR?= MoP1V2FPT0WU
GB-1 MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:y[GlEPTB;MD63NlEzPCEQvF2= MmPhV2FPT0WU
CTB-1 NEPVTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3DXFdKSzVyPUCuO|c6PTVizszN NX21eo9{W0GQR1XS
Becker MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwN{m2NlEh|ryP NID5U3ZUSU6JRWK=
KM12 M2XNTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwOEW0OlYh|ryP NFj3THBUSU6JRWK=
ES7 NEPGWYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwOEm2OUDPxE1? NVjN[llFW0GQR1XS
COLO-684 M3Owdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwOUC2OVgh|ryP Mni2V2FPT0WU
HCC2998 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PXeGlEPTB;MD65N|g2PCEQvF2= M1fwdnNCVkeHUh?=
TE-10 NIHOOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HhOmlEPTB;MD65OlQ{KM7:TR?= M2W1cnNCVkeHUh?=
SF126 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjXNFJFUUN3ME2wMlk5QTdzIN88US=> NGGwTnBUSU6JRWK=
EKVX NWKwWmJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M123PWlEPTB;MT6wN|Q1OiEQvF2= MlnYV2FPT0WU
KARPAS-45 M{\1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnThTWM2OD1zLkC0NFE3KM7:TR?= MlHnV2FPT0WU
KGN NUS4c2JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLuTWM2OD1zLkC1NFQ2KM7:TR?= M1\VenNCVkeHUh?=
ES1 NGG3OlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{joZ2lEPTB;MT6wO|kzOSEQvF2= NVeyR|FbW0GQR1XS
L-540 NEHlZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITpeppKSzVyPUGuNVE5OzlizszN NIHOZmJUSU6JRWK=
KURAMOCHI Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WyO2lEPTB;MT6xNlM4PCEQvF2= NIr2VZBUSU6JRWK=
LU-65 NW\HRnRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPrTWM2OD1zLkGyO|U{KM7:TR?= MWTTRW5ITVJ?
MFH-ino NHfWOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfocIh3UUN3ME2xMlE4PTBzIN88US=> MWrTRW5ITVJ?
NCI-H23 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwMkC0NUDPxE1? NEjYcFRUSU6JRWK=
IA-LM NGPpZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwMkSxNVYh|ryP M1;zOHNCVkeHUh?=
PSN1 NF6wRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDvTWM2OD1zLkK3NFE3KM7:TR?= NUTi[HJHW0GQR1XS
NCI-H719 NGqy[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFwMke0NVEh|ryP NVzyVnBkW0GQR1XS
SW684 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXCTWM2OD1zLkK4OlU6KM7:TR?= MlGwV2FPT0WU
HCE-4 NEW5VWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHNTWM2OD1zLkOwNlIyKM7:TR?= MVHTRW5ITVJ?
EW-16 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrCT4hoUUN3ME2xMlMyOzR5IN88US=> MnjHV2FPT0WU
NCI-H128 M{TLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLBUXJ4UUN3ME2xMlM2QDF2IN88US=> Mnr0V2FPT0WU
HC-1 Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7zTWM2OD1zLkO4NVch|ryP M{TWdXNCVkeHUh?=
IST-MES1 NVTS[I9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf0VXNKSzVyPUGuOFAzODhizszN MmTvV2FPT0WU
Raji M4fKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XabGlEPTB;MT60NVg2KM7:TR?= MXjTRW5ITVJ?
DMS-114 M2DXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXzTWM2OD1zLkS0OVM6KM7:TR?= MYHTRW5ITVJ?
GI-1 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvCTJFKSzVyPUGuOFcyOzFizszN M3vaNnNCVkeHUh?=
NCI-H2081 NWjF[HdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFwNUWxPVYh|ryP MWXTRW5ITVJ?
LC-1F M{TLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D4XmlEPTB;MT61OVE6QCEQvF2= M3rMNXNCVkeHUh?=
NCI-H2227 NEDGPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO1TWM2OD1zLk[xOVYyKM7:TR?= MV;TRW5ITVJ?
D-502MG NHO0eIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L2eGlEPTB;MT62O|IyOSEQvF2= MonRV2FPT0WU
NCI-H2141 NEnKbXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITrdmhKSzVyPUGuOlc{OTdizszN NELVdo5USU6JRWK=
LS-411N NXu4eYJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[2dmlEPTB;MT62PVgxPyEQvF2= M333SXNCVkeHUh?=
SU-DHL-1 M{HrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXVTWM2OD1zLkexNlgyKM7:TR?= MlTkV2FPT0WU
BB30-HNC NIH6TWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXORZdtUUN3ME2xMlczPjh3IN88US=> NHK3bXpUSU6JRWK=
TE-15 MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TCTmlEPTB;MT65NlM4OyEQvF2= MlHuV2FPT0WU
JVM-3 M37HVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i3dGlEPTB;MT65N|kxPCEQvF2= NYjqd3JlW0GQR1XS
IST-SL2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPj[oc5UUN3ME2yMlAyOjV{IN88US=> Ml3zV2FPT0WU
EW-18 NEX2eo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjvNWlnUUN3ME2yMlAzOzN5IN88US=> M2nVdXNCVkeHUh?=
DJM-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJwMEK1OVIh|ryP MW\TRW5ITVJ?
no-11 NXfxe4h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;RZ5lFUUN3ME2yMlA{OTB2IN88US=> NX;uVY1xW0GQR1XS
QIMR-WIL M1PUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LJO2lEPTB;Mj6xOlc3OiEQvF2= M2r0VnNCVkeHUh?=
MC-CAR M37KTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC3OmoxUUN3ME2yMlIzQTVizszN Mn\FV2FPT0WU
KM-H2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3xNVFKSzVyPUKuNlkxPDNizszN MWfTRW5ITVJ?
ECC12 NX2yXVhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3ZOnZKSzVyPUKuN|c6PCEQvF2= NGjxZZVUSU6JRWK=
HCE-T MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\mVmlEPTB;Mj60OFg5OyEQvF2= MVTTRW5ITVJ?
MFM-223 Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkCxTWM2OD1{LkWwPFcyKM7:TR?= MV3TRW5ITVJ?
SW982 M3TXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrRTWM2OD1{LkWxOFgh|ryP M3:0bHNCVkeHUh?=
KG-1 NH2wVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknTTWM2OD1{Lki4O|kyKM7:TR?= MnPFV2FPT0WU
ES4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nmVWlEPTB;Mz6wOlEyOSEQvF2= NWjDPYhxW0GQR1XS
SCC-3 NYfoeWFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLKSJdKSzVyPUOuNVA5PDhizszN MnezV2FPT0WU
RH-1 M4ewOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PqdGlEPTB;Mz6zPFc1QCEQvF2= MUnTRW5ITVJ?
NCI-H748 M{PUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fLRmlEPTB;Mz60OFI3PiEQvF2= M4fxfHNCVkeHUh?=
HCC2218 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTNwNE[5N|ch|ryP NV3qWW5GW0GQR1XS
MEG-01 NHPRcFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XwV2lEPTB;Mz61PVY5KM7:TR?= MYfTRW5ITVJ?
NB12 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoriTWM2OD1|LkW5PFg5KM7:TR?= NWHLNJNuW0GQR1XS
SNB75 NHzEPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTNwNkCxNFMh|ryP Ml7MV2FPT0WU
KMS-12-PE M1\ybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDLd5FlUUN3ME2zMlY4PzJ|IN88US=> NGPB[G5USU6JRWK=
SKM-1 Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH3TWM2OD1|LkexN|c3KM7:TR?= NHW5WmdUSU6JRWK=
COLO-320-HSR NIrSSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle1TWM2OD1|Lke1OlM1KM7:TR?= NFy0d2VUSU6JRWK=
NKM-1 NHfXe|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m1dmlEPTB;Mz63O|M4QCEQvF2= MkDtV2FPT0WU
TE-6 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjKTWM2OD1|Lkm0OVYyKM7:TR?= M1jhbXNCVkeHUh?=
D-336MG MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LERmlEPTB;ND6wNVE3PiEQvF2= MojnV2FPT0WU
NCI-H1650 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlToTWM2OD12LkG1O|k4KM7:TR?= MXjTRW5ITVJ?
ES3 NVLzdoRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jPRmlEPTB;ND6zNlgzPCEQvF2= NWrrR4ViW0GQR1XS
YT NF6xO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnWyTWM2OD12LkO1OFI1KM7:TR?= NWLHdY1jW0GQR1XS
ES5 M3jPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTRwNECyOVUh|ryP NIS3TFJUSU6JRWK=
LB647-SCLC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTRwNU[zNFgh|ryP M3vlUXNCVkeHUh?=
HAL-01 M{jZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTRwNUewN|Qh|ryP NHvJPGRUSU6JRWK=
LP-1 MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTRwN{KzO|Eh|ryP MYPTRW5ITVJ?
BC-1 NEnW[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTOTWM2OD13LkCwOFQ4KM7:TR?= NWi4RWJ1W0GQR1XS
EB-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTDTWM2OD13LkCzNFQyKM7:TR?= NHW1XIRUSU6JRWK=
GT3TKB M33ncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTVwMUe2OlIh|ryP M3vTNnNCVkeHUh?=
NCI-H209 MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTVwMUmzOVIh|ryP M2rtRnNCVkeHUh?=
BT-474 NX\IeWw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfheXhpUUN3ME21MlI{OTB{IN88US=> NGrjOYlUSU6JRWK=
RKO MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHX[lRKSzVyPUWuNlM1OjJizszN MmX3V2FPT0WU
SIMA M4\2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTVwM{C3OlUh|ryP NUfDN3RDW0GQR1XS
RL M2TzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojaTWM2OD13LkO3OVQyKM7:TR?= MXXTRW5ITVJ?
GCIY MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf4XFRWUUN3ME21MlQ4OjN4IN88US=> MXXTRW5ITVJ?
Calu-6 MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\Wb2pKSzVyPUWuOlIzKM7:TR?= MkjKV2FPT0WU
ALL-PO M4i2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTFTWM2OD13Lk[zO|k2KM7:TR?= NFHLRmJUSU6JRWK=
ARH-77 NGnEfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTIbHpKSzVyPUWuOlcxQDdizszN Mm\mV2FPT0WU
A4-Fuk Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf1TWM2OD14LkC4NVE5KM7:TR?= MoTWV2FPT0WU
NCI-H1581 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrtbXdKSzVyPU[uNlM5PDlizszN MoTZV2FPT0WU
HUTU-80 Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\pZmlEPTB;Nj6zOlg6PyEQvF2= MljSV2FPT0WU
TGW NV;FOYxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nPT2lEPTB;Nj60OVU6OyEQvF2= MoXCV2FPT0WU
SK-N-FI MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTZwNEW4OVQh|ryP NXL0UYJHW0GQR1XS
U-266 NHjlVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTZwNUG5NlYh|ryP M33kbXNCVkeHUh?=
EM-2 M1;JSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrSUYFKSzVyPU[uOlcxQTlizszN NGTNbJRUSU6JRWK=
NMC-G1 NWfOS2tiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjUbIl7UUN3ME22MlcyQDl3IN88US=> MmnlV2FPT0WU
KASUMI-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHQTWM2OD14Lki0O|g4KM7:TR?= M3nYTHNCVkeHUh?=
NALM-6 M{jWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSzTWM2OD14Lki2O|U1KM7:TR?= NFrPeYJUSU6JRWK=
OCI-AML2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzReXFKSzVyPUeuNFA{OjZizszN MnLGV2FPT0WU
SHP-77 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjwe5E1UUN3ME23MlIzPDNizszN M13VNXNCVkeHUh?=
NOMO-1 NXHZc3BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTdwMkSyOVQh|ryP NXrWUJpLW0GQR1XS
SK-N-DZ NYP6NpNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTdwN{GwPFkh|ryP NVH3N2NTW0GQR1XS
LB1047-RCC NIL1[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTdwN{KyN|Eh|ryP MUPTRW5ITVJ?
MZ1-PC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTdwOE[1OVgh|ryP NFXLc2pUSU6JRWK=
NB10 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;0cWlEPTB;Nz65PVU2PiEQvF2= MnH0V2FPT0WU
RL95-2 NGTvR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTDRZRKSzVyPUiuNVA5PDJizszN NHPuWYhUSU6JRWK=
OMC-1 M2jEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRThwNUKxPVEh|ryP M3PDPXNCVkeHUh?=
D-283MED M4rmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRThwOUG3NVkh|ryP MnH5V2FPT0WU
MC116 NWjDcoFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULwUGY1UUN3ME24Mlk4QTRizszN MoH5V2FPT0WU
SJSA-1 MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfvU3NpUUN3ME25MlA6ODlzIN88US=> MVXTRW5ITVJ?
JiyoyeP-2003 NV30VYFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTlwMkmzNVch|ryP MlXRV2FPT0WU
IST-MEL1 NUT4ZnZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\Pb2lEPTB;OT63OFE6QCEQvF2= NXTMWIdUW0GQR1XS
CTV-1 MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrQc4g4UUN3ME2xNE4xQTd7IN88US=> M{jLdHNCVkeHUh?=
NH-12 NHrYVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\oc3BnUUN3ME2xNE4zPDN|IN88US=> M4fYVnNCVkeHUh?=
CA46 MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSyfmlKSzVyPUGwMlM3OSEQvF2= NHHhO5ZUSU6JRWK=
NCI-SNU-1 MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGxdGtKSzVyPUGwMlQ6PjlizszN MUPTRW5ITVJ?
SCLC-21H MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LQW2lEPTB;MUCuOlU6PiEQvF2= NETKfWFUSU6JRWK=
EC-GI-10 NGi4VolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:zW3JGUUN3ME2xNE44ODNzIN88US=> MnHRV2FPT0WU
SR M{[yUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrZTWM2OD1zMT6wNVg2KM7:TR?= NHzieHpUSU6JRWK=
NCI-H1648 M4jzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO1TWM2OD1zMT6wPVY2KM7:TR?= MnHqV2FPT0WU
TGBC1TKB MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LlSmlEPTB;MUGuOFExOiEQvF2= M2X1OnNCVkeHUh?=
EW-11 NGOyUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFzLkWxPFYh|ryP MWfTRW5ITVJ?
SK-MM-2 NVzOflhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFzLkiwOlEh|ryP NV25TGdPW0GQR1XS
NCI-H524 M3ThcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILoc3dKSzVyPUGxMlk5OjJizszN MomxV2FPT0WU
NOS-1 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF{LkCzOFUh|ryP MoT4V2FPT0WU
AM-38 NYK5Z5JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfHN2Z2UUN3ME2xNk42PjN|IN88US=> MX\TRW5ITVJ?
A498 NXO4NWlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTF{LkewOlkh|ryP M1TVS3NCVkeHUh?=
KARPAS-422 NWTO[3pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDE[phxUUN3ME2xNk44PDl4IN88US=> NFP5O2ZUSU6JRWK=
LU-139 NGnvd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF{LkmwNlYh|ryP NGO3O2RUSU6JRWK=
COR-L88 M3rRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i4emlEPTB;MUKuPVM5OiEQvF2= MX3TRW5ITVJ?
K5 NYj6V2RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LndGlEPTB;MUKuPVQ3OiEQvF2= NV7IPYtYW0GQR1XS
NB13 M4LDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXSze2lqUUN3ME2xNk46Pzh|IN88US=> NFvEcWJUSU6JRWK=
MRK-nu-1 M1Hafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jNbGlEPTB;MUOuNVk2KM7:TR?= MnfwV2FPT0WU
MHH-NB-11 M1iyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF|LkK5NFIh|ryP MoDDV2FPT0WU
KU812 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXXTWM2OD1zMz62NVI1KM7:TR?= MlXEV2FPT0WU
TE-12 MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF|Lk[5PVQh|ryP MVLTRW5ITVJ?
NCI-N87 NEjpbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;qWGFKSzVyPUGzMlc{PiEQvF2= MoLGV2FPT0WU
EB2 M3rBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTF|Lki1NFUh|ryP NG\PS|JUSU6JRWK=
DB MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF|Lkm4PFUh|ryP NFXDVZlUSU6JRWK=
697 M2Gwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17xe2lEPTB;MUSuOFUyOSEQvF2= NXTyemNqW0GQR1XS
MSTO-211H MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z0[WlEPTB;MUSuO|Q1QCEQvF2= MmfqV2FPT0WU
JVM-2 Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjkOGlKSzVyPUG0Mlc4OzVizszN NIrFUFBUSU6JRWK=
COLO-824 MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqyTWM2OD1zND63PVk1KM7:TR?= M13ETXNCVkeHUh?=
BC-3 NHfUUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rCTWlEPTB;MUWuN|k5KM7:TR?= MnPtV2FPT0WU
BOKU M1rsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DVSmlEPTB;MUWuPVYxQCEQvF2= M2e3XHNCVkeHUh?=
GOTO NXLld|dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnLNFRKSzVyPUG2Mlk3OTdizszN NGTHfmJUSU6JRWK=
HCC2157 NW[0fI1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF5LkS3OVUh|ryP MWDTRW5ITVJ?
LS-1034 NVHj[|VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq2SFBKSzVyPUG3MlY5OThizszN M3PwcnNCVkeHUh?=
CAL-148 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7XbYlKSzVyPUG3Mlk4QTZizszN NXPKXXp6W0GQR1XS
MOLT-4 MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T6d2lEPTB;MUiuPFIxQCEQvF2= M1LCfnNCVkeHUh?=
Daudi MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF6LkmyN|Eh|ryP NEixXm1USU6JRWK=
J-RT3-T3-5 NGfUWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTNb4I6UUN3ME2xPU41ODZ4IN88US=> NIfUU25USU6JRWK=
KMOE-2 M1rWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PFfmlEPTB;MUmuOlQ5OiEQvF2= NHLXb2hUSU6JRWK=
HL-60 NHn2OWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ixU2lEPTB;MkCuNVk3PSEQvF2= M{f2fXNCVkeHUh?=
P31-FUJ MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPqRZlKSzVyPUKwMlQ4PTNizszN M4TtZnNCVkeHUh?=
IM-9 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULGUG4{UUN3ME2yNE43OjJ2IN88US=> M3\WfHNCVkeHUh?=
HDLM-2 NW\keFJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\rTWM2OD1{MD64PFIyKM7:TR?= NHHaNZNUSU6JRWK=
NCI-H1304 NYDzXWxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP0R3RKSzVyPUKxMlA{OTFizszN MXPTRW5ITVJ?
NCI-H345 NYXtVnNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJzLkC2OFMh|ryP NVLHflRjW0GQR1XS
RPMI-6666 NHPuNnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7OV2gxUUN3ME2yNU4{PjB{IN88US=> NW\H[npsW0GQR1XS
GR-ST MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES4cXFKSzVyPUKxMlQyPyEQvF2= MVPTRW5ITVJ?
CHP-126 Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJzLk[xPFEh|ryP MnrJV2FPT0WU
EHEB NVPxOpFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO5XVBHUUN3ME2yNU43PzNzIN88US=> NGXGOFJUSU6JRWK=
CPC-N NVvJUYVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\aUYZPUUN3ME2yOE4xOjBzIN88US=> NVn3[4RFW0GQR1XS
NB1 M3HENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ2Lk[5N|kh|ryP M4HCWnNCVkeHUh?=
LS-123 NGjIZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MleyTWM2OD1{ND65NFEzKM7:TR?= NUDrXWh6W0GQR1XS
ST486 M2r5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjrW3VKSzVyPUK1MlEyOTNizszN NIX2enhUSU6JRWK=
NCI-H1963 MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJ4LkC2NlMh|ryP M{\qTnNCVkeHUh?=
U-87-MG NWHrUZF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX0TWM2OD1{Nj63OlQ1KM7:TR?= NYjHfpl2W0GQR1XS
COR-L279 NFXpT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn5blFKSzVyPUK2Mlc6OjJizszN NIPadZVUSU6JRWK=
LU-165 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnZTWM2OD1{OD6wPFYyKM7:TR?= MVfTRW5ITVJ?
COLO-800 NXvZPZpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTHTWM2OD1{OD6yPVU3KM7:TR?= MVTTRW5ITVJ?
ETK-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILDXGpKSzVyPUK4MlM1PDZizszN NI\vRYNUSU6JRWK=
LNCaP-Clone-FGC MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJ7LkmyPFEh|ryP M2TjVHNCVkeHUh?=
SIG-M5 Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHpTFlKSzVyPUOwMlc6PTJizszN NVPmRnBvW0GQR1XS
NB6 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHL3ZW9KSzVyPUOwMlk2ODNizszN Ml;hV2FPT0WU
NCI-H2107 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjNTWM2OD1|MT6yN|M5KM7:TR?= NV\VU3E3W0GQR1XS
SNU-C1 NYDx[m5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\GTWM2OD1|MT6zNVI3KM7:TR?= NUH4TJo1W0GQR1XS
JAR NEP1dlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjnV21KSzVyPUOxMlM4QTlizszN M4XoRnNCVkeHUh?=
L-363 NYfRUHliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjlTWM2OD1|Mj6yNVQ1KM7:TR?= NVvNV5Y6W0GQR1XS
EW-24 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTN{LkO0O|Qh|ryP MYrTRW5ITVJ?
NB69 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3Td45KSzVyPUOzMlY1PTRizszN M{DjXXNCVkeHUh?=
EW-13 M4TMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j5PGlEPTB;M{OuPFk3QSEQvF2= M3m2NHNCVkeHUh?=
Ramos-2G6-4C10 MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH4TWM2OD1|ND6yPVk{KM7:TR?= Ml\oV2FPT0WU
TE-11 NFS2dHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3iOlJKSzVyPUO0MlQ5OjJizszN MULTRW5ITVJ?
L-428 NUOxNJFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfVOGRKSzVyPUO0Mlc2OzZizszN NUnaTlR2W0GQR1XS
KP-N-YN M3TndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlftTWM2OD1|ND65NFU4KM7:TR?= NGP5dXRUSU6JRWK=
CGTH-W-1 M3\uWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHlcWI6UUN3ME2zOk46ODR6IN88US=> M1LsUHNCVkeHUh?=
K-562 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjPU3pKSzVyPUO3MlA5PjRizszN M4rRdnNCVkeHUh?=
NCI-H1299 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTN6LkG2NFMh|ryP NG\UWlhUSU6JRWK=
RCC10RGB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTITWM2OD1|OD6yNFg{KM7:TR?= NEX6VlVUSU6JRWK=
NCI-SNU-16 NHzIXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO0XJNKSzVyPUO4MlU3PTNizszN M2Xuc3NCVkeHUh?=
LC-2-ad NXLGVJZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTjTWM2OD1|OT60N|M4KM7:TR?= MUDTRW5ITVJ?
MHH-PREB-1 M3vhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTN7LkezPFgh|ryP MoG3V2FPT0WU
NCI-H64 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmOxTWM2OD12MD6wPVQ5KM7:TR?= MlvIV2FPT0WU
LB996-RCC M2O5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3e0XWlEPTB;NECuPFcyPiEQvF2= MojlV2FPT0WU
DEL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWT0RnIzUUN3ME20NU41PDB3IN88US=> NEDPWJRUSU6JRWK=
MLMA NYTMVpI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jo[GlEPTB;NEGuO|U6PSEQvF2= MlPDV2FPT0WU
SBC-1 M13XO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnzTWM2OD12Mj6xPFA3KM7:TR?= MYLTRW5ITVJ?
MPP-89 MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHZTWM2OD12Mj61PFc2KM7:TR?= MnHuV2FPT0WU
MV-4-11 NHi5VnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\i[3VKSzVyPUSyMlkxPjdizszN MXTTRW5ITVJ?
EoL-1- M1\sfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTR2LkG1Olgh|ryP NGrqc21USU6JRWK=
CW-2 M1\SOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3WTWM2OD12ND64N|QzKM7:TR?= NEjsUXVUSU6JRWK=
HT NHHmc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\q[Jd4UUN3ME20OU44ODB5IN88US=> NWDrZmZbW0GQR1XS
SW954 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C1S2lEPTB;NEeuOFEzQCEQvF2= MYLTRW5ITVJ?
A3-KAW MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP0b4dvUUN3ME20PU45ODZzIN88US=> MkO0V2FPT0WU
TC-YIK NHnC[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DiXWlEPTB;NUCuNFM3OyEQvF2= MoPkV2FPT0WU
SW962 NY\VRpp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTV2LkizOVch|ryP NYPHRYhoW0GQR1XS
KP-N-RT-BM-1 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTV4Lk[2N|gh|ryP NWL4ZY1{W0GQR1XS
NCI-H1395 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1GyXmlEPTB;NUiuPFE4OiEQvF2= M4HLU3NCVkeHUh?=
RPMI-8402 NYfiNXFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTV6Lkm1NlYh|ryP NHiwUIxUSU6JRWK=
SCH NFLYXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTZyLkm2N|gh|ryP NVm4U|RGW0GQR1XS
NCI-H2196 MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7STWM2OD14MT6yN|Eh|ryP M2f6VXNCVkeHUh?=
LOXIMVI MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV21XHQ5UUN3ME22NU45OjZ4IN88US=> MoniV2FPT0WU
TGBC24TKB M2rQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfqNFhrUUN3ME22Nk4yPDlzIN88US=> MUfTRW5ITVJ?
SK-MEL-2 NEG1NXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrLTWM2OD14Mz65PFkzKM7:TR?= NHPDTWFUSU6JRWK=
U-698-M M1nkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjlO2VKSzVyPU[4MlU3QDdizszN NF;WSmdUSU6JRWK=
NCI-H1522 NGTZXoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO1XVNKSzVyPU[5MlAxPDdizszN MWXTRW5ITVJ?
UACC-812 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnyR40xUUN3ME22PU42OjB7IN88US=> MUPTRW5ITVJ?
MHH-CALL-2 NEDFPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTdyLkC2JO69VQ>? MlT2V2FPT0WU
NB5 NGDMOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTdyLkO0Olgh|ryP MVrTRW5ITVJ?
KARPAS-299 NF71N3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XRUGlEPTB;N{CuOFQ1PyEQvF2= MVLTRW5ITVJ?
NCI-H1694 NXr2N3d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn35TWM2OD15MT6wN|Ih|ryP NIrq[Y5USU6JRWK=
NCI-H82 NVXufXpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID4OodKSzVyPUexMlk2ODdizszN MX;TRW5ITVJ?
SCC-15 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHicXJLUUN3ME23Nk4{PCEQvF2= NGSyTGpUSU6JRWK=
NCI-H1436 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTQTWZzUUN3ME23Nk44PDV4IN88US=> Ml[1V2FPT0WU
ATN-1 MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj1SG9sUUN3ME23OE42ODVizszN MlGzV2FPT0WU
RPMI-8866 NWnnTmVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTd2Lke1NFkh|ryP MVnTRW5ITVJ?
HCC1599 NID3NWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTd2Lki3N|Ih|ryP M3PLNnNCVkeHUh?=
NCI-H1155 NXfPbHJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTd2LkmzOlch|ryP NGXIVmNUSU6JRWK=
DOHH-2 NEXq[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L5S2lEPTB;N{SuPVUyPCEQvF2= MYfTRW5ITVJ?
SK-NEP-1 NHfOcYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\odWlEPTB;N{WuNFc2PCEQvF2= NI\jc|lUSU6JRWK=
HCC1187 NUHZXoRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnsO3hsUUN3ME23O{43OTJ{IN88US=> MlvJV2FPT0WU
NCI-H322M M2nPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS4TWM2OD15OD6zO|A6KM7:TR?= Ml;QV2FPT0WU
NCI-H526 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHMfXRMUUN3ME23PE42QDd5IN88US=> MUXTRW5ITVJ?
NCI-H2171 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fRfGlEPTB;N{muOFE{PiEQvF2= MmfEV2FPT0WU
COLO-668 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;CXJFsUUN3ME24NU42QDh2IN88US=> NH\ibnBUSU6JRWK=
RS4-11 MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXWbmtxUUN3ME24Nk4zPTB3IN88US=> M3vzbXNCVkeHUh?=
NCI-H716 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXK[mRkUUN3ME24Nk46ODd3IN88US=> MXHTRW5ITVJ?
LU-134-A MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrRTWM2OD16Mz6xN|UyKM7:TR?= NFG5R5NUSU6JRWK=
RPMI-8226 NW[yO29iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTh2LkKxNFch|ryP M4juOXNCVkeHUh?=
KY821 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTlzLk[1OVEh|ryP MYTTRW5ITVJ?
ECC4 MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XrfGlEPTB;OUOuPFI3QSEQvF2= M1f2UHNCVkeHUh?=
EW-3 NE\wR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTl2LkmwPFEh|ryP M4TqN3NCVkeHUh?=
NB7 NF:5OlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLxTWM2OD17NT63O|g3KM7:TR?= NVj4S3NXW0GQR1XS
NCI-H720 M4rjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLxTWM2OD17OD60NFYyKM7:TR?= NEexb21USU6JRWK=
NCI-H446 NXnx[lYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17rZmlEPTB;OUmuO|U5QCEQvF2= NHXpNmFUSU6JRWK=
NCI-H889 NIe1NmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnGXHVFUUN3ME2xNFQvOjR{IN88US=> M2\qUnNCVkeHUh?=
EW-22 NV;KN5BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HZ[mlEPTB;MUC2MlE6KM7:TR?= MXzTRW5ITVJ?
BV-173 NEfJOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTFyOD63Nlgh|ryP MYrTRW5ITVJ?
WSU-NHL M1jle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\zV2tKSzVyPUGwPU43PzFizszN Mn7mV2FPT0WU
MN-60 M12wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXaTWM2OD1zMEmuOlkh|ryP NFrzV3RUSU6JRWK=
DG-75 NYi5Z4tjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonGTWM2OD1zMUOuN|UzKM7:TR?= MYrTRW5ITVJ?
DMS-79 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\1TWM2OD1zMUeuN|gzKM7:TR?= MlHsV2FPT0WU
SK-MEL-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFzOD6wNFkh|ryP NEHZcIxUSU6JRWK=
DMS-153 M4flRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M162ZWlEPTB;MUKxMlc1PSEQvF2= NV33[GVyW0GQR1XS
NCI-H510A M12xWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF{Nz6zNkDPxE1? MnvnV2FPT0WU
BE-13 M1z6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TwU2lEPTB;MUO0MlA1PCEQvF2= NF7U[WRUSU6JRWK=
KP-N-YS M4HOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TxcmlEPTB;MUO5Mlc{PiEQvF2= M2K5WnNCVkeHUh?=
SUP-T1 M4HRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjTRYxyUUN3ME2xOFMvPzB6IN88US=> NFX1O3NUSU6JRWK=
EW-12 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M330S2lEPTB;MUS0MlY6QSEQvF2= MXXTRW5ITVJ?
NB14 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;RWGRKSzVyPUG0O{4xQDJizszN NXPScYxrW0GQR1XS
MDA-MB-134-VI MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF2OD6yOlgh|ryP NXXwNJM3W0GQR1XS
NCI-H1770 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF3Nj6yO|kh|ryP M4radnNCVkeHUh?=
TUR M{fkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHnZ|BKSzVyPUG2O{45PyEQvF2= NVjuZpdSW0GQR1XS
NCI-H1417 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPEcVdKSzVyPUG4NE4{OzFizszN MlnrV2FPT0WU
IMR-5 M2niTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF6MT61O|Eh|ryP MVXTRW5ITVJ?
NCI-H226 NWH6S3RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq0O|JKSzVyPUG4PE45PjZizszN M1XHRnNCVkeHUh?=
NCI-H187 M3jCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K3SWlEPTB;MUmwMlA3PCEQvF2= NULwOW95W0GQR1XS
SF539 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3STWM2OD1zOUKuO|I5KM7:TR?= MoLHV2FPT0WU
TALL-1 M{fjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLBeGFKSzVyPUG5PE4{ODRizszN M2n6PHNCVkeHUh?=
TE-441-T M{TrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF7OT63N|kh|ryP NV63WWx{W0GQR1XS
REH MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\udGlEPTB;MkO2MlYzPiEQvF2= NXXTdZBPW0GQR1XS
MS-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TXfmlEPTB;MkO5MlEzOSEQvF2= M3LjWHNCVkeHUh?=
THP-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\GVI9KSzVyPUK2OE44OzhizszN Mn3pV2FPT0WU
NCI-H1838 NXTzeVB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ5MT60OVYh|ryP M1mxVXNCVkeHUh?=
P30-OHK MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJ6Mz64OFch|ryP MXLTRW5ITVJ?
C8166 NET1VWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTNZphUUUN3ME2zOFUvOzN6IN88US=> NWXHbGxSW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western Blot
Bcr-Abl; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Ac-histone H3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-caspase3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-PARP; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

ASCL1; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

CgA; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

Nrf2; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

HO-1; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

26722260 19765735 23604711
Immunofluorescence
Bak; 

PubMed: 20557369     


Proteasome inhibitor induces Bak activation. Cells were treated with either vehicle or MG-132 at 10 µmol/L for 12 hours and were subjected to Bak immunofluorescence study using antiserum specific for the N terminus of Bak. Upon Bak activation, this epitope is no longer masked within the protein and becomes available for antibody binding upon Bak conformational change.

C2GnT-M/NMIIA; 

PubMed: 22525330     


Confocal images of bC2GnT-M and NMIIA in cells treated with DMSO (D) or MG-132 (E).

AGS3/Vimentin; 

PubMed: 20065032     


COS-7 cells were transfected with wild-type or TPR-modified AGS3 (AGS3-TPR [M1 to E470] or AGS3-GPR [E470 to S650]) in pEGFP-N1. Thirty-six hours after transfection, cells were incubated with MG 132 (10 μM) for 12 h, and then the cells were processed for immunofluorescence microscopy. The images presented are representative of 2 to 10 separate transfections.

20557369 22525330 20065032
Growth inhibition assay
Apoptosis assay; 

PubMed: 20557369     


LX-2 cells were incubated for 24 hours in the presence of increasing concentrations of MG-132 (0, 2.5, 5, 10 µmol/L) and in the presence of the pan-caspase inhibitor QVD at 5 µmol/L for 24 hours. MG-132 and QVD were prepared in DMSO as a vehicle. All data were expressed as mean ± standard error from three individual experiments. * p < 0.01 (10 µmol/L MG-132 treated cells vs. 10 µmol/L MG-132 plus QVD treated cells)

Cell viability; 

PubMed: 26137056     


The proteasome inhibitor MG-132 significantly decreased the cell viability in EC9706 cells in a dose- and time-dependent manner.

cell proliferation ; 

PubMed: 19765735     


MG-132 significantly inhibits growth of carcinoid tumor cells in vitro. Pulmonary (NCI-H727) and GI (BON) carcinoid tumor cells were treated with MG-132 at the indicated concentrations (0 to 4µM) for up to 6 days and cell viability was measured every 2 days with the MTT assay (P<0.001). The results show that MG-132 leads to the suppression cellular proliferation in NCI-H727 (A) and BON (B) cells. (OD, optical density)

20557369 26137056 19765735
ELISA
IL-8; 

PubMed: 11160671     


ELISA of IL-8 from supernatant of eTat cells. eTat cells were blocked with Hu (2 mM) and released. MG-132 (50 μM) was added at the time of release. The supernatant was collected at 3 h postrelease and analyzed for IL-8 protein using ELISA. The result shown is representative of three independent experiments ± standard deviation. 

IL-1beta; 

PubMed: 22606244     


LPS-primed WT BMDM were incubated in control medium or medium containing 10 ng/ml ricin or 25 µg/ml cycloheximide for 4 h. MG-132 (30 µM) or Bortezimib (0.5 µM) was included as indicated. Secreted IL-1ß was measured by ELISA in triplicate wells.

11160671 22606244
In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

+ Expand
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24 and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Formulation: Dissolved in DMSO, and diluted in PBS
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products4

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID